CD8A and neoplasm: The ability of CD8 to synergize with even very low affinity TCRs [Kd > 300 μM (25, 67, 68)] can be advantageous in the normal anti-tumor setting, as most anti-self (and, hence, anti-tumor) pepMHC reactive T cells would have been deleted in the thymus if they exhibited even modest affinities.